Trial Profile
Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Lenzilumab (Primary) ; Ascorbic acid; Ascorbic acid
- Indications Chronic myelomonocytic leukaemia
- Focus Therapeutic Use
- Acronyms PREACH-M
- 12 Dec 2023 Results (n=15) shoeing cytokine profiles and systemic C-reactive protein levels in newly diagnosed CMML patients treated with Lenzilumab, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results describing improvements in variant allele frequencies (VAF) for RAS-pathway mutations and hematologic improvements associated with LENZ/AZA treatment in CMML, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Interim results (n=11) presented at the 65th American Society of Hematology Annual Meeting and Exposition